We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
ITPA Activity in Children Treated by Azathioprine: Relationship to the Occurrence of Adverse Drug Reactions and Inflammatory Response.
- Authors
Citterio‐Quentin, Antony; Moulsma, Mustapha; Gustin, Marie‐Paule; Lachaux, Alain; Boulieu, Roselyne
- Abstract
Abstract: Azathioprine (AZA), a thiopurine drug, is widely used in the treatment of children with immunological diseases such as inflammatory bowel disease (IBD) and autoimmune hepatitis (AIH); however, interindividual variability in the occurrence of adverse drug reactions (ADRs) and drug response is observed. This study investigated (i) the relationships between inosine triphosphate pyrophosphatase (ITPA) activity, an enzyme involved in thiopurine metabolism, and the occurrence of ADRs in children with immunological disease on AZA therapy, and (ii) the relationship between ITPA activity and the inflammatory activity observed in children with IBD. ITPA and TPMT activities were determined in 106 children with immunological disease on AZA therapy. Markers of hepatotoxicity, myelotoxicity, pancreatitis and inflammation as well as clinical information were retrospectively collected during regular medical visits. No significant association was found between ITPA activity and hepatotoxicity or clinical ADRs such as cutaneous reactions, arthralgia, flulike symptoms and gastrointestinal disorders. Concerning myelotoxicity, a significant relation was observed between ITPA activity and RBC mean corpuscular volume (MCV;<italic> p</italic>=0.003). This observation may be related to the significant relationship found between high ITPA activity and the increase in γ‐globulin level reflecting inflammation (<italic>p</italic>=0.005). In our study, ITPA activity was not associated with occurrence of ADRs, but a relationship between high ITPA activity and γ‐globulin, a marker of inflammation, was found in children with IBD. Therefore, measurement of ITPA activity may help to identify children with IBD predisposed to residual inflammation on AZA therapy. Further prospective studies are needed to confirm this result.
- Subjects
AZATHIOPRINE; IMMUNOLOGIC diseases in children; DRUG side effects; MYELOSUPPRESSION; HEPATOTOXICOLOGY
- Publication
Basic & Clinical Pharmacology & Toxicology, 2018, Vol 122, Issue 6, p588
- ISSN
1742-7835
- Publication type
Article
- DOI
10.1111/bcpt.12958